AbstractBackgroundAge-related macular degeneration (AMD) remains a primary cause of blindness, with neovascular AMD (nAMD) presenting particular treatment challenges. Despite anti-vascular endothelial growth factor (anti-VEGF) therapies, many patients exhibit a suboptimal response to the previously available anti-vascular endothelial growth factor (anti-VEGF) therapies.

摘要背景年龄相关性黄斑变性（AMD）仍然是致盲的主要原因，新生血管性AMD（nAMD）提出了特殊的治疗挑战。尽管有抗血管内皮生长因子（抗VEGF）疗法，但许多患者对先前可用的抗血管内皮生长因子（抗VEGF）疗法的反应不佳。

This study evaluates the efficacy and treatment interval extension of faricimab in this patient cohort.MethodsIn a retrospective single-centre study at University Hospitals of Bristol and Weston, UK, nAMD patients suboptimally responsive to previous anti-VEGF therapies were switched to faricimab. Treatment started with an initiation phase of 4 monthly injections followed by a ‘Treat and Extend’ protocol.

本研究评估了该患者队列中faricimab的疗效和治疗间隔延长。方法在英国布里斯托尔和韦斯顿大学医院进行的一项回顾性单中心研究中，对先前抗VEGF治疗反应不佳的nAMD患者改用faricimab。。

Outcomes included best-recorded visual acuity (BRVA), central subfield thickness (CST), the presence of retinal fluid, and treatment intervals.ResultsAmong 98 eyes of 79 patients, following faricimab treatment, significant reductions in CST and retinal fluid were noted, indicating decreased disease activity.

结果包括最佳记录视力（BRVA），中央亚视野厚度（CST），视网膜液的存在和治疗间隔。结果在79例患者的98只眼中，接受faricimab治疗后，CST和视网膜液明显减少，表明疾病活动性降低。

While BRVA changes were not statistically significant, the anatomical improvements suggest a potential therapeutic benefit. Notably, 40% of patients achieved extended treatment intervals, reducing the treatment burden.ConclusionFaricimab offers a promising alternative for nAMD patients with suboptimal responses to prior anti-VEGF treatments, demonstrating significant anatomical improvements and the possibility of extended dosing intervals.

虽然BRVA的变化在统计学上并不显着，但解剖学上的改进表明潜在的治疗益处。值得注意的是，40%的患者延长了治疗间隔，减轻了治疗负担。结论faricimab为先前抗VEGF治疗反应不佳的nAMD患者提供了一种有前途的替代方案，显示出显着的解剖学改善和延长给药间隔的可能性。

These findings highlight the need for prospective real-world studies to further assess faricimab’s role in nAMD management and its long-term impact on patient outcomes..

这些发现强调了前瞻性现实世界研究的必要性，以进一步评估faricimab在nAMD管理中的作用及其对患者预后的长期影响。。

Access through your institution

通过您的机构访问

Buy or subscribe

购买或订阅

This is a preview of subscription content, access via your institution

这是订阅内容的预览，可通过您的机构访问

Access options

访问选项

Access through your institution

通过您的机构访问

Access through your institution

通过您的机构访问

Change institution

变革机构

Buy or subscribe

购买或订阅

Subscribe to this journalReceive 18 print issues and online access251,40 € per yearonly 13,97 € per issueLearn moreBuy this articlePurchase on Springer LinkInstant access to full article PDFBuy nowPrices may be subject to local taxes which are calculated during checkout

订阅本期刊每年可收到18期印刷版和在线访问251,40欧元每期仅13,97欧元了解更多在Springer Links上购买本文即时访问全文PDFBuy NOW价格可能需要缴纳结帐时计算的当地税费

Additional access options:

其他访问选项：

Log in

登录

Learn about institutional subscriptions

了解机构订阅

Read our FAQs

阅读我们的常见问题

Contact customer support

联系客户支持

Fig. 1: Central subfield thickness (CST) at baseline (0), throughout the initiation phase of faricimab (1–3) and at first review (8 weeks post-initiation) (4) and second review (5).Fig. 2: Percentage of patient with SRF and IRF at baseline (0), throughout the initiation phase of faricimab (1–3), at first review (8 weeks post-initiation) (4) and second review (5).Fig.

图1：基线（0），整个faricimab起始阶段（1-3）和第一次检查（起始后8周）（4）和第二次检查（5）的中心亚区厚度（CST）。图2:SRF和IRF患者在基线（0），整个faricimab起始阶段（1-3），第一次复查（起始后8周）（4）和第二次复查（5）的百分比。图。

3: Treatment interval of patients at baseline, 8 weeks post initiation and sub-sequent review..

3： 基线时患者的治疗间隔，开始后8周和随后的复查。。

Data availability

数据可用性

The datasets generated during and analysed during the current study are not publicly available due to reasons of sensitivity but are available from the corresponding author on reasonable request.

由于敏感性原因，当前研究期间生成和分析的数据集无法公开获得，但可根据合理要求从通讯作者处获得。

ReferencesQuartilho A, Simkiss P, Zekite A, Xing W, Wormald R, Bunce C. Leading causes of certifiable visual loss in England and Wales during the year ending 31 March 2013. Eye. 2016;30:602–7.Article

参考文献Quartilho A，Simkiss P，Zekite A，Xing W，Wormald R，Bunce C.截至2013年3月31日，英格兰和威尔士可证明视力丧失的主要原因。眼睛。2016年；30:602–7.文章

CAS

中科院

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng C-Y, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:e106–e16.Article

Wong WL，Su X，Li X，Cheung CMG，Klein R，Cheng C-Y等。2020年和2040年全球年龄相关性黄斑变性患病率和疾病负担预测：系统评价和荟萃分析。柳叶刀全球健康。2014年；2： e106–e16.文章

PubMed

PubMed

Google Scholar

谷歌学者

Lorés-Motta L, Riaz M, Grunin M, Corominas J, van Asten F, Pauper M, et al. Association of Genetic Variants With Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration. JAMA Ophthalmol. 2018;136:875–84.Article

。JAMA眼科。2018年；136:875-84.文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Johnston RL, Lee AY, Buckle M, Antcliff R, Bailey C, McKibbin M, et al. UK Age-Related Macular Degeneration Electronic Medical Record System (AMD EMR) Users Group Report IV: Incidence of Blindness and Sight Impairment in Ranibizumab-Treated Patients. Ophthalmology. 2016;123:2386–92.Article .

Johnston RL，Lee AY，Buckle M，Antcliff R，Bailey C，McKibbin M等。英国年龄相关性黄斑变性电子病历系统（AMD EMR）用户组报告IV：雷珠单抗治疗患者的失明和视力障碍发生率。眼科学。2016年；123:2386-92。文章。

PubMed

PubMed

Google Scholar

谷歌学者

Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.

Heier JS，Khanani AM，Quezada Ruiz C，Basu K，Ferrone PJ，Brittain C等。玻璃体内法利单抗治疗新生血管性年龄相关性黄斑变性（TENAYA和LUCERNE）的疗效，耐久性和安全性：两项随机，双盲，3期，非劣效性试验。

Lancet. 2022;399:729–40.Article .

柳叶刀。2022年；399:729-40。文章。

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database Syst Rev. 2017;6:Cd007419.PubMed

Virgili G，Parravano M，Evans JR，Gordon I，Lucenteforte E.抗血管内皮生长因子治疗糖尿病性黄斑水肿：网络荟萃分析。Cochrane数据库系统2017年版；6： Cd007419.PubMed

Google Scholar

谷歌学者

Monés J, Singh RP, Bandello F, Souied E, Liu X, Gale R. Undertreatment of Neovascular Age-Related Macular Degeneration after 10 Years of Anti-Vascular Endothelial Growth Factor Therapy in the Real World: The Need for A Change of Mindset. Ophthalmologica. 2020;243:1–8.Article

Monés J，Singh RP，Bandello F，Souied E，Liu X，Gale R.在现实世界中抗血管内皮生长因子治疗10年后，新生血管性年龄相关性黄斑变性的治疗不足：需要改变心态。眼科。2020年；243:1-8.文章

PubMed

PubMed

Google Scholar

谷歌学者

Mehta H, Nguyen V, Barthelmes D, Pershing S, Chi GC, Dopart P, et al. Outcomes of Over 40,000 Eyes Treated for Diabetic Macula Edema in Routine Clinical Practice: A Systematic Review and Meta-analysis. Adv Ther. 2022;39:5376–90.Article

。高级Ther。2022年；39:5376–90.文章

CAS

中科院

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Yang S, Zhao J, Sun X. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des, Dev Ther. 2016;10:1857–67.CAS

Yang S，Zhao J，Sun X.新生血管性年龄相关性黄斑变性对抗VEGF治疗的耐药性：综述。药物Des，Dev Ther。2016年；10： 1857年至67年

Google Scholar

谷歌学者

Khanani AM, Aziz AA, Khan H, Gupta A, Mojumder O, Saulebayeva A, et al. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study – 6 month results. Eye. 2023;37:3574–81.Article

Khanani AM，Aziz AA，Khan H，Gupta A，Mojumder O，Saulebayeva A等。faricimab在新生血管性年龄相关性黄斑变性中的实际疗效和安全性：TRUCKEE研究–6个月结果。眼睛。2023年；37:3574–81.文章

CAS

中科院

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Leung EH, Oh DJ, Alderson SE, Bracy J, McLeod M, Perez LI, et al. Initial Real-World Experience with Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration. Clin Ophthalmol. 2023;17:1287–93.Article

Leung EH，Oh DJ，Alderson SE，Bracy J，McLeod M，Perez LI等。Faricimab治疗难治性新生血管性年龄相关性黄斑变性的初步现实经验。临床眼科。2023年；17：

CAS

中科院

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Download references

下载参考资料

Funding

资金

CG, Travel Bursary and Lecture fees from Roche Products and Santen. CB, Advisory Board, Travel Bursary, Honoraria and Lecture Fees from Bayer, Roche Products, Norvatis, Alimera Sciences, Janssen, Apellis, Boehringer-Ingelheim. SS, Advisory Board and Lecture Fees from Bayer, Roche Products and Alimera..

罗氏产品和桑顿的CG、旅行助学金和讲座费。拜耳、罗氏产品、诺瓦蒂斯、阿里梅拉科学、杨森、阿佩利斯、勃林格殷格翰的CB、咨询委员会、旅行助学金、酬金和讲座费。拜耳（Bayer）、罗氏（Roche Products）和阿里梅拉（Alimera）的SS、咨询委员会和演讲费。。

Author informationAuthors and AffiliationsBristol Eye Hospital, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UKChristine Goodchild, Clare Bailey, Eslam Ahmed & Serena SalvatoreRoyal Victoria Eye and Ear Hospital, Adelaide Road, Dublin, IrelandChristine GoodchildDepartment of Medicine, University of Bristol, Bristol, UKJimena Soto Hernaez & Serena SalvatoreAuthorsChristine GoodchildView author publicationsYou can also search for this author in.

作者信息作者和附属机构布里斯托尔大学医院布里斯托尔和韦斯顿NHS基金会信托基金，布里斯托尔，UKChristine Goodchild，克莱尔·贝利，Eslam Ahmed＆Serena SalvatoreRoyal维多利亚眼耳医院，都柏林阿德莱德路，IrelandChristine Goodchild布里斯托尔大学医学系，UKJimena Soto Hernaez＆Serena Salvatoreauthors Christine GoodchildView作者出版物您也可以在中搜索这位作者。

PubMed Google ScholarClare BaileyView author publicationsYou can also search for this author in

PubMed Google ScholarClare BaileyView作者出版物您也可以在

PubMed Google ScholarJimena Soto HernaezView author publicationsYou can also search for this author in

PubMed Google ScholarJimena Soto HernaezView作者出版物您也可以在

PubMed Google ScholarEslam AhmedView author publicationsYou can also search for this author in

PubMed Google ScholarEslam AhmedView作者出版物您也可以在

PubMed Google ScholarSerena SalvatoreView author publicationsYou can also search for this author in

PubMed Google ScholarSerena SalvatoreView作者出版物您也可以在

PubMed Google ScholarContributionsCG was responsible for designing the study, conducting the search, data collection, extracting and analysing data, interpreting results, writing the manuscript, creating Tables 1 and 2 and Figs. 1 and 2, creating and updating reference lists.

PubMed Google ScholarContributionsCG负责设计研究，进行搜索，数据收集，提取和分析数据，解释结果，撰写手稿，创建表1和2以及图1和2，创建和更新参考列表。

CB was responsible for designing the study, interpreting result, manuscript revision. JSH was responsible for data collection. ES was responsible for data collection. SS was responsible for designing the study, conducting the search, data collection, extracting and analysing data, interpreting results, writing, and revising the manuscript, tables and figures.Corresponding authorCorrespondence to.

CB负责设计研究，解释结果，稿件修订。JSH负责数据收集。ES负责数据收集。SS负责设计研究，进行搜索，数据收集，提取和分析数据，解释结果，撰写和修改手稿，表格和数字。对应作者对应。

Christine Goodchild.Ethics declarations

克里斯汀·古德奇尔德。道德宣言

Competing interests

相互竞争的利益

The authors declare no competing interests.

作者声明没有利益冲突。

Additional informationPublisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Rights and permissionsSpringer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.Reprints and permissionsAbout this articleCite this articleGoodchild, C., Bailey, C., Soto Hernaez, J.

Additional informationPublisher的注释Springer Nature在已发布的地图和机构隶属关系中的管辖权主张方面保持中立。权利和许可Pringer Nature或其许可人（例如协会或其他合作伙伴）根据与作者或其他权利持有人的出版协议对本文拥有专有权；本文接受稿件版本的作者自行存档仅受此类出版协议和适用法律的条款管辖。转载和许可本文引用本文Goodchild，C.，Bailey，C.，Soto Hernaez，J。

et al. Real world efficacy and durability of faricimab in patients with neovascular AMD (nAMD) who had sub-optimal response to prior anti-VEGF therapy..

faricimab在新生血管性AMD（nAMD）患者中的实际疗效和持久性，这些患者对先前的抗VEGF治疗反应不佳。。

Eye (2024). https://doi.org/10.1038/s41433-024-03218-7Download citationReceived: 03 January 2024Revised: 27 May 2024Accepted: 26 June 2024Published: 04 July 2024DOI: https://doi.org/10.1038/s41433-024-03218-7Share this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy to clipboard.

眼睛（2024）。https://doi.org/10.1038/s41433-024-03218-7Download引文收到日期：2024年1月3日修订日期：2024年5月27日接受日期：2024年6月26日发布日期：2024年7月4日OI：https://doi.org/10.1038/s41433-024-03218-7Share本文与您共享以下链接的任何人都可以阅读此内容：获取可共享链接对不起，本文目前没有可共享的链接。复制到剪贴板。

Provided by the Springer Nature SharedIt content-sharing initiative

由Springer Nature SharedIt内容共享计划提供